Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact Us
Early Edition  //  Current Issue  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited

Medicine Research ›› 2021, Vol. 5 ›› Issue (1): 200023-200023.DOI: 10.21127/yaoyimr20200023

• Perspective • Previous Articles     Next Articles

Prodrug Systems (II): A Perspective of Polymer-Based Doxorubicin Prodrug Systems towards Chemotherapy

Zhao Wang,a Filipe Olim,b Jingjing Sun,c Ana Rute Neves,b Fátima Mendes,b Helena Tomás,*,b and Ruilong Sheng*,b   

  1. a School of Material Engineering, Jinling Institute of Technology, Nanjing, Jiangsu 211169, China
    b CQM - Centro de Química da Madeira, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal
    c Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States
  • Received:2020-12-22 Revised:2021-01-31 Online:2021-01-20 Published:2021-01-20
  • Contact: ruilong.sheng@staff.uma.pt (R. S.)
  • Supported by:

Abstract: Utilizing biocompatible polymers as platforms to covalently conjugate with chemotherapeutics to construct polymer-based prodrugs and their nano drug delivery systems has attracted great attention in recent years. This perspective reviewed state-of-the-arts for polymer-based doxorubicin prodrugs and the related nanodelivery systems, including: (1) pH-responsive polymer-doxorubicin prodrugs/conjugates; (2) pH/redox- dual responsive prodrugs/conjugates; (3) reactive oxygen species/hypoxia-responsive polymer-doxorubicin prodrugs; (4) tumor receptor targeting polymer prodrugs; (5) enzyme-responsive polymer-doxorubicin prodrugs. Finally, possible future perspectives were also stated and discussed.


Key words: polymers, doxorubicin, prodrug, stimuli-responsive, drug delivery, nanosystem

Copyright © Medicine Research, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States